公司近日发布公告称，其LinX持续葡萄糖监测系统已获得巴西的上市批准，适用于成人及儿童的连续 动态血糖监测。公告指出，巴西是拉丁美洲的核心市场，根据国际糖尿病联盟《2025全球糖尿病地图》 数据，巴西20–79岁糖尿病患者约1,662万人，患病率达10.7%，患病人数居全球第六；2024年糖尿病相 关支出达约451亿美元，位居全球第三。此次获批将有助于公司进一步拓展拉丁美洲市场，推动国际业 务的规模化扩张与收入增长。公司表示将继续聚焦糖尿病监测、治疗及管理领域的技术创新与全球发 展。董事会提醒投资者，产品生产、销售及收益受市场变化等因素影响，股东及潜在投资者应审慎行 事。 最新公告列表 《自愿性公告 本公司持续葡萄糖监测系统海外获批》 截至2025年12月24日收盘，微泰医疗-B（02235）报收于7.68元，较前一交易日上涨0.52%。该股当日开 盘价为0.0元，最高价0.0元，最低价0.0元，成交额为0元。近52周最高价为9.17元，最低价为4.0元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

智通财经APP讯，微泰医疗-B(02235)公布，集团的的LinX持续葡萄糖监测系统，近期获得巴西的上市 批准，适用于成人及儿童的连续动态血糖监测。 公司LinX持续葡萄糖监测系统在巴西获批上市，将极大强化公司在拉丁美洲的市场布局，为国际业务 的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发 展，持续推动相关领域技术与产品创新。 ...

Core Viewpoint - Weitai Medical-B (2235.HK) has received approval from the National Medical Products Administration for its core product, the Equil insulin pump, expanding its use to children and adolescents aged 3-17 years, thus providing new treatment options for millions of diabetic patients in China [1] Group 1: Product Approval and Market Expansion - The Equil insulin pump was previously approved only for adult diabetes patients, and the recent approval allows it to be used for a younger demographic [1] - This expansion in indications demonstrates the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management [1] - The approval is expected to strengthen the company's leading position in the industry and strategically expand the market space for its products [1] Group 2: Future Focus and Innovation - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management methods [1] - There will be ongoing efforts to drive technological and product innovation in related fields [1]

Group 1 - The core product, Equil patch insulin pump, has received approval from the National Medical Products Administration for use in children and adolescents aged 3-17, expanding its market from adult diabetes patients to millions of domestic children and adolescents with diabetes [1][2] - The clinical trial for this indication was led by Zhejiang University School of Medicine Children's Hospital, in collaboration with six top children's hospitals in the country, demonstrating the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] - The patch insulin pump offers advantages over traditional tubing insulin pumps, including more precise and safe insulin delivery, convenience in wearing, cost-effectiveness, enhanced privacy, and elimination of issues like clogging and tubing entanglement [1] Group 2 - The expansion of the indication reflects the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management, further solidifying its leading position in the industry and strategically expanding the market space for its products [2] - The company will continue to focus on the global development of diabetes monitoring, treatment, and management methods, driving innovation in related technologies and products [2]

Core Viewpoint - The approval of the Equil patch insulin pump for children and adolescents expands its application from adult diabetes patients to a new demographic, providing millions of young diabetes patients in China with a new treatment option [1][2] Group 1: Product Approval and Market Expansion - The Equil patch insulin pump has received approval from the National Medical Products Administration, allowing its use for children and adolescents aged 3-17 years [1] - This approval is expected to significantly enhance the market potential for the product, addressing the needs of millions of domestic children and adolescents with diabetes [1][2] Group 2: Clinical Trials and Efficacy - The clinical trials for this indication were led by the Children's Hospital affiliated with Zhejiang University School of Medicine, in collaboration with six top children's hospitals across the country [1] - The trials demonstrated the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] Group 3: Product Advantages - The patch insulin pump offers several advantages over traditional tube-based insulin pumps, including more precise and safe insulin delivery, ease of use, cost-effectiveness, enhanced privacy, and the absence of issues like clogging and tubing entanglement [1] Group 4: Company Strategy and Future Focus - The expansion of the indication reflects the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management [2] - The company aims to solidify its leading position in the industry and will continue to focus on global developments in diabetes monitoring, treatment, and management, driving innovation in related technologies and products [2]